



## **International Summit on Psychedelic Therapies for Mental Illness 18-19 November 2020 – Melbourne, Australia**

**We are delighted to extend an invitation to you and your colleagues to join us in November 2020.**

Mind Medicine Australia will hold a two-day International Summit on Psychedelic Therapies for Mental Illness in November 2020 in Melbourne, bringing together clinicians, scientists, academics, mental and public health professionals, philanthropists, Government, law and policy leaders, business, industry, consumers and other interested stakeholders.

The event will also feature a **two-day pre-Summit introductory workshop program (16-17 November)** for anyone with an interest in the topic and who is considering further development of their current therapeutic skills or who are eager to gain a detailed understanding of **psychedelic-assisted psychotherapy for the treatment of mental illness**.

The Summit will feature a rich program with a mixture of international and national keynotes, workshops, hot spots, panel conversations and gala dinner with Q & A.

Leading international speakers confirmed for the 2-day summit including Australia Ambassadors include: Head of Neuropsychopharmacology at Imperial College London **Prof David Nutt (UK)**, Executive Director of MAPS **Dr Rick Doblin (USA)**, psychiatrist, researcher and writer **Dr Ben Sessa (UK)**, Head of the Centre for Psychedelic Research at Imperial College London **Dr Robin Carhart-Harris (UK)**, James B. Duke Professor of Psychology and Behavioural Economics at Duke University, **Prof Dan Ariely (USA/Israel)**, Anthropologist, ethnobotanist and Explorer in Residence at the National Geographic Society **Dr Wade Davis (Canada)**, Chairman and CEO of Eleusis **Shlomi Raz (USA)**, leading Psychotherapist and Founder of the UK TRIPP Network **Maria Papaspyrou (UK)**, Clinical Psychologist who was part of the team working on psilocybin trials at Imperial College, **Renee Harvey (UK)**, Associate Director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University School of Medicine, **Prof Matthew Johnson (USA)**, Founder & Executive Director Neuroscape **Adam Gazzaley M.D, PHD (USA)**, Clinical Psychologist, Research Scientist and Author **Dr Adele Lafrance (USA)**, Psychedelic Psychiatrist & Researcher **Dr Reid Robison (USA)**, Director of the University of Auckland's Health Psychology Practitioner Programme **Dr Lisa Reynolds (NZ)**, Deputy Secretary, Health Products Regulation Group - TGA **John Skerritt** and more TBA.

### **Key themes will include:**

- Ethical, legal, and implementation frameworks for psychedelic treatments
- The current state of mental health in Australia and existing treatments
- Clinical outcomes of psychedelic treatment for mental illness
- Therapeutic mechanisms of psychedelic treatments
- Enhancing effectiveness and minimising risks for psychedelic treatment
- The way forwards for Australia: Challenges and preparation towards creating a new paradigm

Psychedelic therapies have been granted **Breakthrough Therapy status by the FDA in the USA** due to current promising research in the **treatment of depression and PTSD**. We look forward to collaborating with you to explore psychedelic treatment options to help address the **mental health crisis we currently face, and offer treatments to those who need it most**.

***Together we can change the paradigm for mental health.***

**Venues:** Sofitel Melbourne On Collins, University location for Therapist 2-day workshop

**For more details and to register for tickets, please visit:** <https://summit.mindmedicineaustralia.org/>